Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients - Research portal of Justus Liebig University Giessen:

Meeting Abstract

Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients

Authors list: Regierer, Anne; Hasseli, Rebecca; Schaefer, Martin; Hoyer, Bimba Franziska; Krause, Andreas; Lorenz, Hanns-Martin; Pfeil, Alexander; Richter, Jutta; Schmeiser, Tim; Strangfeld, Anja; Schulze-Koops, Hendrik; Voll, Reinhard; Specker, Christof; Mueller-Ladner, Ulf

Publication year: 2021

Pages: 197-201

Journal: Arthritis & Rheumatology

Volume number: 73

ISSN: 2326-5191

eISSN: 2326-5205

Conference: ACR Convergence Conference

Publisher: Wiley

Citation Styles

Harvard Citation style: Regierer, A., Hasseli, R., Schaefer, M., Hoyer, B., Krause, A., Lorenz, H., et al. (2021) Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients, Arthritis & Rheumatology, 73, pp. 197-201

APA Citation style: Regierer, A., Hasseli, R., Schaefer, M., Hoyer, B., Krause, A., Lorenz, H., Pfeil, A., Richter, J., Schmeiser, T., Strangfeld, A., Schulze-Koops, H., Voll, R., Specker, C., & Mueller-Ladner, U. (2021). Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients. Arthritis & Rheumatology. 73, 197-201.